Hypothesis: TGF-β induced fibronectin deposition

Query: You are a professional biomedical researcher, having experience in early-stage drug discovery and validation in vitro. Your task is to evaluate cell culture assays that would be used to evaluate drugs to treat glaucoma.
        Given the following assay, do a comprehensive literature review to evaluate if this assay would be useful for testing therapeutics for glaucoma. Search relevant literature across
        biomedical, clinical, and biochemical literature about the disease or therapeutic landscape. Don't look up specific drugs, but any relevant scientific information that may inform assay development.Strategy: TGF-β induced fibronectin deposition
Reasoning: Treat TM monolayers with TGF-β1 to stimulate fibronectin and collagen IV synthesis, then quantify ECM accumulation by immunofluorescence or ELISA. This rapid fibrotic endpoint reflects pathologic ECM remodeling in glaucoma and enables screening of anti‐fibrotic compounds (strickland2022remodelingofthe; Murphy-Ullrich 2022).Provide your response in the following format, like an evaluation for a scientific proposal:
        Assay Overview: Explain the assay idea, including the following key points: which aspect of the disease pathogenesis does the assay model, what measurements will be taken from the assay and how they will be taken, which cells or other biological material are used in the assay.
        Biomedical Evidence: Make a compelling argument for how the aspect of the disease represented in the assay is central to the pathogenesis of the disease. Make sure to consider both the biomedical and clinical literature.
        Previous Use: Explain how this assay has previously been used for drug discovery (if this has been done). Explain any key scientific discoveries which have been made using this assay.
        Overall Evaluation: Strengths and weaknesses of this assay for testing therapeutics for glaucoma.

Assay Overview:
The proposed in vitro assay involves treating trabecular meshwork (TM) monolayers with transforming growth factor-beta (TGF-β1) to induce fibronectin and collagen IV synthesis, thereby mimicking the pathological extracellular matrix (ECM) remodeling observed in glaucoma. Measurements will focus on quantifying ECM accumulation, with endpoints detected by immunofluorescence to assess protein deposition at the cellular level and ELISA to quantify secreted ECM proteins in culture supernatants (faralli2019roleoffibronectin pages 1-3, li2022tgfβ2regulateshuman pages 6-8). The assay uses TM cells, which are central to the regulation of aqueous humor outflow and intraocular pressure (IOP); these cells are sensitive to TGF-β signaling—a key mediator of fibrotic responses in glaucomatous pathology (vranka2015extracellularmatrixin pages 7-9, buffault2022thedualeffect pages 8-10).

Biomedical Evidence:
Glaucoma pathogenesis involves a significant fibrotic component within the trabecular meshwork. In patients with primary open-angle glaucoma, increased levels of TGF-β2 are known to drive ECM remodeling that includes overproduction of fibronectin and collagen, leading to increased outflow resistance and elevated IOP (faralli2019roleoffibronectin pages 1-3, vranka2015extracellularmatrixin pages 9-11). This assay targets a central aspect of the disease by reproducing the fibrotic milieu of the TM. From a biomedical perspective, TGF-β induced ECM remodeling is not only pathognomonic for glaucomatous changes but also correlates with clinical outcomes such as the failure of aqueous humor drainage (hill2015modellingandtreating pages 39-44, nartey2021phenotypiccharacterizationof pages 7-9). Clinical observations, alongside in vitro data, support the notion that targeting ECM accumulation could yield therapeutic benefits that directly impact the underlying mechanism of elevated IOP (li2022tgfβ2regulateshuman pages 11-13).

Previous Use:
The use of TGF-β induced fibronectin deposition assays has a precedent in drug discovery and mechanistic studies. These assays have been employed to delineate mechanisms governing ECM remodeling and cytoskeletal changes in TM cells, facilitating the identification of potential therapeutic candidates that modulate pro-fibrotic signaling pathways (buffault2022thedualeffect pages 8-10, faralli2019roleoffibronectin pages 19-20). ROCK inhibitors, for example, have been shown to reduce fibronectin expression and reverse cytoskeletal alterations induced by TGF-β in TM cells. Additionally, the assay has been validated using both monolayer cultures and more complex 3D ECM models, which offer insights into the mechanical properties and cellular interactions relevant to TM function (ghosh2024ecmbiomaterialsfor pages 4-5, li2022tgfβ2regulateshuman pages 14-15). Prior drug discovery efforts underscore the assay’s utility in screening anti-fibrotic agents and evaluating their effectiveness in reversing ECM alterations, serving as a translational bridge between bench and potential clinical applications (kasetti2020exvivoculturedhuman pages 8-10).

Overall Evaluation:
Strengths of the assay include its direct recapitulation of a key pathobiological process in glaucoma—TGF-β induced ECM remodeling leading to fibronectin deposition—which is directly linked to the clinical manifestations of elevated IOP. The use of both immunofluorescence and ELISA provides robust, complementary endpoints that yield both qualitative and quantitative data. Moreover, the assay’s format is adaptable for high-throughput screening, thereby facilitating the early-stage identification of therapeutic candidates (hill2015modellingandtreating pages 146-153, li2022tgfβ2regulateshuman pages 6-8).

However, the assay possesses some limitations. The monolayer culture system may not fully capture the three-dimensional complexity and biomechanical properties of the TM in vivo. Alternative models, such as 3D hydrogels or ex vivo cultures, may provide additional insights into cell–ECM interactions under more physiologically relevant conditions (ghosh2024ecmbiomaterialsfor pages 1-2, kasetti2020exvivoculturedhuman pages 8-10). Variability in TGF-β responsiveness among primary cell isolates may also affect assay reproducibility, necessitating careful optimization and standardization.

Overall, TGF-β induced fibronectin deposition assays represent a robust and clinically relevant platform for evaluating anti-fibrotic therapeutics in glaucoma, offering clear translational potential for early-stage drug discovery (vranka2015extracellularmatrixin pages 7-9, nartey2021phenotypiccharacterizationof pages 7-9).

References:
1. (buffault2022thedualeffect pages 8-10): Juliette Buffault, Françoise Brignole-Baudouin, Élodie Reboussin, Karima Kessal, Antoine Labbé, Stéphane Mélik Parsadaniantz, and Christophe Baudouin. The dual effect of rho-kinase inhibition on trabecular meshwork cells cytoskeleton and extracellular matrix in an in vitro model of glaucoma. Journal of Clinical Medicine, 11:1001, Feb 2022. URL: https://doi.org/10.3390/jcm11041001, doi:10.3390/jcm11041001. This article has 33 citations and is from a peer-reviewed journal.

2. (faralli2019roleoffibronectin pages 1-3): Jennifer A. Faralli, Mark S. Filla, and Donna M. Peters. Role of fibronectin in primary open angle glaucoma. Cells, 8:1518, Nov 2019. URL: https://doi.org/10.3390/cells8121518, doi:10.3390/cells8121518. This article has 94 citations and is from a peer-reviewed journal.

3. (faralli2019roleoffibronectin pages 19-20): Jennifer A. Faralli, Mark S. Filla, and Donna M. Peters. Role of fibronectin in primary open angle glaucoma. Cells, 8:1518, Nov 2019. URL: https://doi.org/10.3390/cells8121518, doi:10.3390/cells8121518. This article has 94 citations and is from a peer-reviewed journal.

4. (ghosh2024ecmbiomaterialsfor pages 1-2): Souvik Ghosh and Samuel Herberg. Ecm biomaterials for modeling of outflow cell biology in health and disease. Biomaterials and Biosystems, 13:100091, Mar 2024. URL: https://doi.org/10.1016/j.bbiosy.2024.100091, doi:10.1016/j.bbiosy.2024.100091. This article has 2 citations and is from a poor quality or predatory journal.

5. (ghosh2024ecmbiomaterialsfor pages 4-5): Souvik Ghosh and Samuel Herberg. Ecm biomaterials for modeling of outflow cell biology in health and disease. Biomaterials and Biosystems, 13:100091, Mar 2024. URL: https://doi.org/10.1016/j.bbiosy.2024.100091, doi:10.1016/j.bbiosy.2024.100091. This article has 2 citations and is from a poor quality or predatory journal.

6. (hill2015modellingandtreating pages 146-153): LJ Hill. Modelling and treating dysregulated fibrosis in primary open angle glaucoma. Unknown journal, 2015.

7. (hill2015modellingandtreating pages 39-44): LJ Hill. Modelling and treating dysregulated fibrosis in primary open angle glaucoma. Unknown journal, 2015.

8. (kasetti2020exvivoculturedhuman pages 8-10): Ramesh B. Kasetti, Pinkal D. Patel, Prabhavathi Maddineni, and Gulab S. Zode. Ex-vivo cultured human corneoscleral segment model to study the effects of glaucoma factors on trabecular meshwork. PLOS ONE, 15:e0232111, Jun 2020. URL: https://doi.org/10.1371/journal.pone.0232111, doi:10.1371/journal.pone.0232111. This article has 19 citations and is from a peer-reviewed journal.

9. (li2022tgfβ2regulateshuman pages 11-13): Haiyan Li, Jessica L. Henty-Ridilla, Audrey M. Bernstein, Preethi S. Ganapathy, and Samuel Herberg. Tgfβ2 regulates human trabecular meshwork cell contractility<i>via</i>erk and rock pathways with distinct signaling crosstalk dependent on the culture substrate. Current Eye Research, 47:1165-1178, May 2022. URL: https://doi.org/10.1080/02713683.2022.2071943, doi:10.1080/02713683.2022.2071943. This article has 19 citations and is from a peer-reviewed journal.

10. (li2022tgfβ2regulateshuman pages 14-15): Haiyan Li, Jessica L. Henty-Ridilla, Audrey M. Bernstein, Preethi S. Ganapathy, and Samuel Herberg. Tgfβ2 regulates human trabecular meshwork cell contractility<i>via</i>erk and rock pathways with distinct signaling crosstalk dependent on the culture substrate. Current Eye Research, 47:1165-1178, May 2022. URL: https://doi.org/10.1080/02713683.2022.2071943, doi:10.1080/02713683.2022.2071943. This article has 19 citations and is from a peer-reviewed journal.

11. (li2022tgfβ2regulateshuman pages 6-8): Haiyan Li, Jessica L. Henty-Ridilla, Audrey M. Bernstein, Preethi S. Ganapathy, and Samuel Herberg. Tgfβ2 regulates human trabecular meshwork cell contractility<i>via</i>erk and rock pathways with distinct signaling crosstalk dependent on the culture substrate. Current Eye Research, 47:1165-1178, May 2022. URL: https://doi.org/10.1080/02713683.2022.2071943, doi:10.1080/02713683.2022.2071943. This article has 19 citations and is from a peer-reviewed journal.

12. (nartey2021phenotypiccharacterizationof pages 7-9): A Nartey. Phenotypic characterization of segmental human trabecular meshwork cells. Unknown journal, 2021.

13. (vranka2015extracellularmatrixin pages 7-9): Janice A. Vranka, Mary J. Kelley, Ted S. Acott, and Kate E. Keller. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental Eye Research, 133:112-125, Apr 2015. URL: https://doi.org/10.1016/j.exer.2014.07.014, doi:10.1016/j.exer.2014.07.014. This article has 407 citations and is from a peer-reviewed journal.

14. (vranka2015extracellularmatrixin pages 9-11): Janice A. Vranka, Mary J. Kelley, Ted S. Acott, and Kate E. Keller. Extracellular matrix in the trabecular meshwork: intraocular pressure regulation and dysregulation in glaucoma. Experimental Eye Research, 133:112-125, Apr 2015. URL: https://doi.org/10.1016/j.exer.2014.07.014, doi:10.1016/j.exer.2014.07.014. This article has 407 citations and is from a peer-reviewed journal.
